Management of central giant cell granuloma with subcutaneous denosumab therapy

Journal of Oral and Maxillofacial Surgery

Volumn 72, Issue 12, 2014, Pages 2469-2484

  Naidu, Aparna ^a   Malmquist, Michael P ^a   Denham, Claude A ^b,c   Schow, Sterling R ^a  

^a BAYLOR COLLEGE OF DENTISTRY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CORTICOSTEROID; DENOSUMAB; INTERFERON; TRIAMCINOLONE ACETONIDE; VITAMIN D; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BONE REGENERATION; CALCIUM BLOOD LEVEL; CANCER CHEMOTHERAPY; CASE REPORT; CHILD; CONE BEAM COMPUTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DENTITION; DRUG WITHDRAWAL; FACE ASYMMETRY; FEMALE; FOLLOW UP; GIANT CELL GRANULOMA; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; JAW DISEASE; JAW PAIN; LOADING DRUG DOSE; MALOCCLUSION; MANDIBLE CENTRAL GIANT CELL GRANULOMA; MANDIBLE PARESTHESIA; MANDIBLE TUMOR; MEDICAL ONCOLOGIST; ORTHODONTICS; PARATHYROID DISEASE; PHASE 2 CLINICAL TRIAL; PREMOLAR TOOTH; SCHOOL CHILD; TUMOR BIOPSY; TUMOR DIAGNOSIS; VITAMIN SUPPLEMENTATION; GRANULOMA, GIANT CELL; MANDIBULAR NEOPLASMS; RADIOGRAPHY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; CONE-BEAM COMPUTED TOMOGRAPHY; FEMALE; GRANULOMA, GIANT CELL; HUMANS; INJECTIONS, SUBCUTANEOUS; MANDIBULAR NEOPLASMS;

EID: 84922876343     PISSN: 02782391     EISSN: 15315053     Source Type: Journal    
DOI: 10.1016/j.joms.2014.06.456     Document Type: Article

References (55)

1. H.L. Jaffe Giant-cell reparative granuloma, traumatic bone cyst, and fibrous (fibro-osseous) dysplasia of the jawbones Oral Surg 6 1953 159
2. P.L. Auclair, P. Cuenin, and F.J. Kratochvil A clinical and histomorphologic comparison of the central giant cell granuloma and the giant cell tumor Oral Surg Oral Med Oral Pathol 66 1988 197
3. F. Bertoni, D. Present, and A. Sudanese Giant-cell tumor of bone with pulmonary metastases. Six case reports and a review of the literature Clin Orthop Relat Res 237 1988 275
4. S.B. Whitaker, and C.A. Waldron Central giant cell lesions of the jaws. A clinical, radiologic, and histopathologic study Oral Surg Oral Med Oral Pathol 75 1993 199
5. J. De Lange, and H.P. Van den Akker Clinical and radiological features of central giant-cell lesions of the jaw Oral Surg Oral Med Oral Pathol Oral Radiol Endod 99 2005 464
6. B. Neville, D.D. Damm, and C.M. Allen Oral and Maxillofacial Pathology ed 3 2008 626 629
7. R. Chuong, L.B. Kaban, and H. Kozakewich Central giant cell lesions of the jaws: A clinicopathologic study J Oral Maxillofac Surg 44 1986 708
8. L.B. Kaban, M.J. Troulis, and D. Ebb Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws J Oral Maxillofac Surg 60 2002 1103
9. N.A. Athanasou, E. Bliss, and K.C. Gatter An immunohistological study of giant-cell tumour of bone: Evidence for an osteoclast origin of the giant cells J Pathol 147 1985 153
10. S.R. Goldring, A.L. Schiller, and H.J. Mankin Characterization of cells from human giant cell tumors of bone Clin Orthop Relat Res 204 1986 59
11. G.J. Atkins, D.R. Haynes, and S.E. Graves Expression of osteoclast differentiation signals by stromal elements of giant cell tumors J Bone Miner Res 15 2000 640
12. D.M. Thomas, and K.M. Skubitz Giant cell tumour of bone Curr Opin Oncol 21 2009 338
13. J.C. Tiffee, and T.B. Aufdemorte Markers for macrophage and osteoclast lineages in giant cell lesions of the oral cavity J Oral Maxillofac Surg 55 1997 1108
14. B. Liu, S.F. Yu, and T.J. Li Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts J Oral Pathol Med 32 2003 367
15. A.M. Flanagan, S.M.B. Tinkler, and M.A. Horton The multinucleate cells in giant cell granulomas of the jaw are osteoclasts Cancer 62 1988 1139
16. J. de Lange, H.P. van den Akker, and H. van den Berg Central giant cell granuloma of the jaw: A review of the literature with emphasis on therapy options Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104 2007 603
17. J. de Lange, H.P. van den Akker, and H. Klip Incidence and disease-free survival after surgical therapy of central giant-cell granulomas of the jaw in The Netherlands: 1990-1995 Head Neck 26 2004 792
18. A.B. Bataineh, T. Al-Khateeb, and M.A. Rawashdeh The surgical treatment of central giant cell granuloma of the mandible J Oral Maxillofac Surg 60 2002 756
19. M.A. Rawashdeh, A.B. Bataineh, and T. Al-Khateeb Long-term clinical and radiological outcomes of surgical management of central giant cell granuloma of the maxilla Int J Oral Maxillofac Surg 35 2006 60
20. J.R. Jacoway, F.V. Howell, and B.C. Terry Central giant cell granuloma - An alternative to surgical therapy Oral Surg Oral Med Oral Pathol 66 1988 572
21. B.C. Terry, and J.R. Jacoway Management of central giant cell lesions: An alternative to surgical therapy Oral Maxillofac Surg Clin North Am 6 1994 579
22. E.N. Abdo, L.C. Alves, and A.S. Rodrigues Treatment of a central giant cell granuloma with intralesional corticosteroid Br J Oral Maxillofac Surg 43 2005 74
23. T. Hirayama, A. Sabokbar, and N.A. Athanasou Effect of corticosteroids on human osteoclast formation and activity J Endocrinol 175 2002 155
24. O.W. Dempster, B.S. Moonga, and L.S. Stein Glucocorticosteroids inhibit bone resorption by isolated rat osteoclasts by enhancing apoptosis J Endocrinol 154 1997 397
25. R.E. Marx, and D. Stern Oral and Maxillofacial Pathology: A Rationale for Diagnosis and Treatment 2003 Quintessence Publishing Chicago, IL 783 789
26. G.C. Nickolson, M.A. Horton, and P.M. Sexton Calcitonin receptors of human osteoclastoma Horm Metab Res 19 1987 585
27. A. Maeda, H. Matsui, and M. Kanamori Calcitonin receptors on neoplastic mononuclear cells cultured from a human giant cell tumor of the sacrum J Cancer Res Clin Oncol 120 1994 272
28. M.A. Pogrel Calcitonin therapy for central giant cell granuloma J Oral Maxillofac Surg 61 2003 649
29. M. Vered, A. Buchner, and D. Dayan Immunohistochemical expression of glucocorticoid and calcitonin receptors as a tool for selecting therapeutic approach in central giant cell granuloma of the jaw bones Int J Oral Maxillofac Surg 35 2006 756
30. L.B. Kaban, M.J. Troulis, and M.S. Wilkinson Adjuvant antiangiogenic therapy for giant cell tumors of the jaws J Oral Maxillofac Surg 65 2007 2018
31. J. de Lange, H.P. van den Akker, and H. van den Berg Limited regression of central giant cell granuloma by interferon alpha after failed calcitonin therapy: A report of two cases Int J Oral Maxillofac Surg 35 2006 865
32. K.E. Goldman, M.K. Marshall, and E. Alessandrini Complications of alpha-interferon therapy for aggressive giant cell lesion of the maxilla Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100 2005 285
33. H. Abukawa, L.B. Kaban, and W.B. Williams Effect of interferon-alpha-2b on porcine mesenchymal stem cells J Oral Maxillofac Surg 64 2006 1214
34. N.G. da Silva, A.S. Carreira, and E.N. Pedreira Treatment of central giant cell lesions using bisphosphonates with intralesional corticosteroid injections Head Face Med 8 2012 23
35. R. Landesberg, S. Eisig, and I. Fennoy Alternative indications for bisphosphonate therapy J Oral Maxillofac Surg 67 2009 27
36. E.R. Van Beek, C.W. Lowik, and F.H. Ebetino Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: Structure-activity relationships Bone 23 1998 437
37. D. Castellano, J.M. Sepulveda, and I. García-Escobar The role of RANK-ligand inhibition in cancer: The story of denosumab Oncologist 16 2011 136
38. J.E. Brown, and R.E. Coleman Denosumab in patients with cancer - A surgical strike against the osteoclast Nat Rev Clin Oncol 9 2012 110
39. L. Huang, J. Xu, and D.J. Wood Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-κB in giant cell tumor of bone: Possible involvement in tumor cell-induced osteoclast-like cell formation Am J Pathol 156 2000 761
40. A. Stopeck, J.J. Body, and Y. Fujiwara Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: Results of a randomized phase 3 study Eur J Cancer Suppl 7 2009 2
41. D. Henry, R. von Moos, and S. Vadhan-Raj A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma Eur J Cancer Suppl 7 2009 12
42. S. Khosla, D. Burr, and J. Cauley Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research Bone Miner Res 22 2007 1479
43. D. Thomas, R. Henshaw, and K. Skubitz Denosumab in patients with giant-cell tumour of bone: An open-label, phase 2 study Lancet Oncol 11 2010 275
44. S. Chawla, R. Henshaw, and L. Seeger Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: Interim analysis of an open-label, parallel-group, phase 2 study Lancet Oncol 14 2013 901
45. S. Kitazawa, and R. Kitazawa RANK ligand is a prerequisite for cancer-associated osteolytic lesions J Pathol 198 2002 228
46. A.T. Stopeck, A. Lipton, and J.J. Body Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study J Clin Oncol 28 2010 5132
47. K. Fizazi, M. Carducci, and M. Smith Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study Lancet 377 2011 813
48. D.H. Henry, L. Costa, and F. Goldwasser Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma J Clin Oncol 29 2011 1125
49. P.D. Miller, M.A. Bolognese, and E.M. Lewiecki Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial Bone 43 2008 222
50. J.P. Brown, R.L. Prince, and C. Deal Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial J Bone Miner Res 24 2009 153
51. American Association of Oral and Maxillofacial Surgeons: Medication-related osteonecrosis of the jaw - 2014 Update. Available at: http://www.aaoms.org/docs/position-papers/mronj-position-paper.pdf?pdf=MRONJ-Position-Paper. Accessed April 21, 2014
52. S. Papapoulos, R. Chapurlat, and C. Libanati Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension J Bone Miner Res 27 2012 694
53. P.D. Delmas Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases J Clin Densitom 11 2008 325
54. A. Lipton, S. Siena, and M. Rader Comparison of denosumab versus zoledronic acid (za) for treatment of bone metastases in advanced cancer patients: An integrated analysis of 3 pivotal trials [abstract 1249P] Ann Oncol 21 suppl 8 2010 viii380
55. L.F. Tse, K.C. Wong, and S.M. Kumta Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: A case-control study Bone 42 2008 68